New CMO Dietmar Berger highlights Gilead’s ‘unique situation’ and its HIV ambitionsnews2025-02-12T09:30:33+00:00February 12th, 2025|Endpoints News|
SpringWorks lands FDA approval for nerve tumor treatmentnews2025-02-12T02:25:12+00:00February 12th, 2025|Endpoints News|
Travere plans to seek expanded label for kidney drugnews2025-02-11T20:57:01+00:00February 11th, 2025|Endpoints News|
Biohaven gets FDA priority review for neuro disease drug after refuse-to-filenews2025-02-11T20:50:05+00:00February 11th, 2025|Endpoints News|
What will pharma’s share buyback shopping spree mean for M&A?news2025-02-11T16:20:23+00:00February 11th, 2025|Endpoints News|
Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthosnews2025-02-11T12:21:43+00:00February 11th, 2025|Endpoints News|
Vertex operations chief Stuart Arbuckle to retirenews2025-02-11T00:24:41+00:00February 11th, 2025|Endpoints News|
Judge halts some NIH cuts after 22 states suenews2025-02-10T22:54:24+00:00February 10th, 2025|Endpoints News|
Merck KGaA confirms interest in acquiring cancer biotech SpringWorksnews2025-02-10T20:50:58+00:00February 10th, 2025|Endpoints News|
Eli Lilly inks $630M deal for Phase 1 MASH candidatenews2025-02-10T20:15:03+00:00February 10th, 2025|Endpoints News|
